Guardant Health, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
GH$158.79+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| As of December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $378,203 | $525,540 |
| Short-term marketable debt securities | 823,395 | 314,438 |
| Accounts receivable, net | 137,849 | 110,253 |
| Inventory, net | 85,876 | 71,083 |
| Prepaid expenses and other current assets, net | 40,723 | 33,800 |
| Total current assets | 1,466,046 | 1,055,114 |
| Restricted cash | 111,214 | 104,215 |
| Property and equipment, net | 145,915 | 136,813 |
| Right-of-use assets, net | 158,849 | 142,265 |
| Intangible assets, net | 25,921 | 6,760 |
| Goodwill | 77,257 | 3,290 |
| Other assets, net | 28,457 | 37,152 |
| Total Assets | $2,013,659 | $1,485,609 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $54,442 | $38,551 |
| Accrued compensation | 119,646 | 83,219 |
| Accrued expenses | 77,889 | 68,345 |
| Deferred revenue | 50,753 | 35,468 |
| Total current liabilities | 302,730 | 225,583 |
| Convertible senior notes, net | 1,504,000 | 1,142,547 |
| Long-term operating lease liabilities | 178,463 | 164,292 |
| Other long-term liabilities | 127,773 | 92,834 |
| Total Liabilities | 2,112,966 | 1,625,256 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ deficit: | ||
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2025 and 2024 | — | — |
| Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of December 31, 2025 and 2024; 130,635,301 and 123,994,006 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1 | 1 |
| Additional paid-in capital | 2,900,056 | 2,443,788 |
| Accumulated other comprehensive loss | (4,852) | (5,201) |
| Accumulated deficit | (2,994,512) | (2,578,235) |
| Total Stockholders’ Deficit | (99,307) | (139,647) |
| Total Liabilities and Stockholders’ Deficit | $2,013,659 | $1,485,609 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.